{"id":"W4205108145","doi":"10.1016/j.jtho.2021.12.011","title":"Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Foundation Medicine; Eli Lilly and Company; Ignyta; Takeda Pharmaceuticals U.S.A.; Merck Sharp and Dohme; Institut Gustave-Roussy; Genentech; BeiGene; Regeneron Pharmaceuticals; CMC Microsystems; Aptitude Health; AbbVie; Boehringer Ingelheim; Amgen; Ariad Pharmaceuticals; Chugai Pharmaceutical; Roche; EMD Serono; Novartis; Sanofi; Merck; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Continuation; Disease; Progressive disease; Atherosclerotic cardiovascular disease; MEDLINE","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001040046,0.0001319453,0.0004550523,0.0001760246,0.0002159729,0.0003776764,0.0001918512,0.0002198226,0.0006696615],"category_scores_gemma":[0.0009802096,0.00005928719,0.0004473223,0.000224066,0.0001545747,0.0002376552,0.0002028067,0.0004583017,0.000125305],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005300801,"about_ca_system_score_gemma":0.0005484931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006290234,"about_ca_topic_score_gemma":0.001181961,"domain_scores_codex":[0.9996617,0.0001019984,0.00004086323,0.00006793215,0.00007926321,0.00004828384],"domain_scores_gemma":[0.9993157,0.0001937373,0.0002344126,0.00003609381,0.00006241093,0.0001575186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05579376,0.001257617,0.5696693,0.001060712,0.0009089906,0.002605607,0.0003765971,0.002268831,0.04603083,0.0003406557,0.002014646,0.3176725],"study_design_scores_gemma":[0.00518748,0.06145909,0.8946916,0.000285299,0.001235971,0.007427457,0.0001623492,0.002072346,0.01174855,0.0004851101,0.01521379,0.00003101108],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940565,0.004333718,0.0001438556,0.0001234782,0.00001431601,0.00004098504,0.0002150227,0.000009315429,0.001062889],"genre_scores_gemma":[0.9986607,0.0005981954,0.00009744209,0.00008491379,0.0000241099,0.00001706471,0.0003772599,0.000001311043,0.0001390893],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001040046,"threshold_uncertainty_score":0.005500317,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01440997373445262,"score_gpt":0.4454697753667234,"score_spread":0.4310598016322708,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}